Role of macrophages in early protective immune responses induced by two vaccines against foot and mouth disease

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 262-270

  Quattrocchi, V ^a   Langellotti, C ^b   Pappalardo, J S ^a   Olivera, V ^a   Di Giacomo, S ^a   van Rooijen, N ^c   Mongini, C ^b   Waldner, C ^b   Zamorano, P I ^a,b  

^a INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Early protection; FMDV; Macrophages

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; FOOT AND MOUTH DISEASE VACCINE; IMS 12802PR; INACTIVATED VIRUS VACCINE; ISA 206VG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; HOST; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS INACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FOOT-AND-MOUTH DISEASE; LEUKOCYTE REDUCTION PROCEDURES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OPSONIN PROTEINS; PHAGOCYTOSIS; VACCINES, INACTIVATED; VIRAL VACCINES;

FOOT-AND-MOUTH DISEASE VIRUS; MURINAE; MUS;

EID: 80054948770     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.007     Document Type: Article

References (47)

1. Alexandersen S., Zhang Z., Donaldson A.I., Garland A.J.M. The pathogenesis and diagnosis of foot-and-mouth disease. J. Comp. Pathol. 2003, 129:1-36.
2. Amadori M., Archetti I.L., Verardi R., Berneri C. Isolation of mononuclear cytotoxic cells from cattle vaccinated against foot-and-mouth disease. Arch. Virol. 1992, 122:293-306.
3. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672.
4. Barnett P., Keel V.P., Reid S., Armstrong R.M., Statham R.J., Voyce C., Aggarwal N., Cox S.J. Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the " carrier" state in sheep. Vaccine 2004, 22:1221-1232.
5. Barnett P.V., Cox S.J., Aggarwal N., Gerber H., McCullough K.C. Further studies on the early protective responses of pigs following immunization with high potency foot and mouth disease vaccine. Vaccine 2002, 20:3197-3208.
6. Bautista E.M., Ferman G.S., Golde W.T. Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV). Vet. Immunol. Immunopathol. 2003, 92:61-73.
7. Borca M.V., Fernandez F.M., Sadir A.M., Braun M., Schudel A.A. Immune response to foot-and-mouth disease virus in a murine experimental model: effective thymus-independent primary and secondary reaction. Immunology 1986, 59:261-267.
8. Carrillo C., Wigdorovitz A., Oliveros J.C., Zamorano P.I., Sadir A.M., Gomez N., Salinas J., Escribano J.M., Borca M.V. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J. Virol. 1998, 72(2):1688-1690.
9. Collen T., Pullen L., Doel T.R. T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model. J. Gen. Virol. 1989, 70:395-403.
10. Chung K.M., Nybakken G.E., Thompson B.S., Engle M.J., Marri A., Fremont D.H., Diamond M.S. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J. Virol. 2006, 80(3):1340-1351.
11. Daemen T., Hofstede G., Ten Kate M.T., Bakker-Woudenberg I.A., Scherphof G.L. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 1995, 61(5):716-721.
12. Decheneux, C., Quattrocchi, V., Olivera V., Di giacomo, S., Kahn, N., Smitsaart, E., Zamorano, P.I., 2010. Vaccination against foot-and-mouth disease virus, association between humoral immune response in cattle and mice. Presented in the symposium: Practical Alternatives to Reduce Animal Testing in Quality Control of Veterinary Biologicals in the Americas. Bs. As., Argentina.
13. Denkers E.Y., Badger C.C., Ledbetter J.A., Bernstein I.D. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 1985, 135(3):2183-2186.
14. Diaz-San Segundo F., Rodriguez-Calvo T., de Avila A., Sevilla N. Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10. PLoS One 2009, 4(5):5659-5662.
15. Doel T.R. Foot-and-mouth disease virus. Curr. Top. Microbiol. Immunol. 2005, 288:103-132.
16. Doel T.R., Williams L., Barnett P.V. Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 1994, 12(7):592-600.
17. Fernandez F.M., Borca M.V., Sadir A.M., Fondevila N., Mayo J., Schudel A.A. Foot-and-mouth disease virus (FMDV) experimental infection: susceptibility and immune response of adult mice. Vet. Microbiol. 1986, 12(1):15-24.
18. Golde W.T., Pacheco J.M., Duque H., Doel T., Penfold B., Ferman G.S., Gregg D.R., Rodriguez L.L. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 2005, 23(50):5775-5782.
19. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17(2):465-493.
20. House, J.A. and Mebus, C.A., 1998. Foot-and-mouth disease. In: C. O. F. A. D. I. T. U. S. A. H. Association, Richmond, VA, USA (Ed.), Foreign Animal Diseases. Pat Campbell & Associates and Carter Printing Company, 213-224.
21. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166(12):7381-7388.
22. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172(9):5598-5605.
23. Juleff N., Windsor M., Lefevre E.A., Gubbins S., Hamblin P., Reid E., McLaughlin K., Beverley P.C., Morrison I.W., Charleston B. Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naive cattle. J. Virol. 2009, 83(8):3626-3636.
24. Law M., Hangartner L. Antibodies against viruses: passive and active immunization. Curr. Opin. Immunol. 2008, 20(4):486-492.
25. Lopez O.J., Sadir A.M., Borca M.V., Fernandez F.M., Braun M., Schudel A.A. Immune response to foot-and-mouth disease virus in an experimental murine model II. Basis of persistent antibody reaction. Vet. Immunol. Immunopathol. 1990, 24(4):313-321.
26. Lutz J., Augustin A.J., Jager L.J., Bachmann D., Brandl M. Acute toxicity and depression of phagocytosis in vivo by liposomes: influence of lysophosphatidylcholine. Life Sci. 1995, 56(2):99-106.
27. Maradei E., La Torre J., Robiolo B., Esteves J., Seki C., Pedemonte A., Iglesias M., D'Aloia R., Mattion N. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina. Vaccine 2008, 26:6577-6586.
28. Martin F., Kearney J.F. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a " natural immune memory" Immunol. Rev. 2000, 175:70-79.
29. McCullough K.C., Crowther J.R., Butcher R.N., Carpenter W.C., Brocchi E., Capucci L., De Simone F. Immune protection against foot-and-mouth disease virus studied using virus-neutralizing and non-neutralizing concentrations of monoclonal antibodies. Immunology 1986, 58(3):421-428.
30. McCullough K.C., De Simone F., Brocchi E., Capucci L., Crowther J.R., Kihm U. Protective immune response against foot-and-mouth disease. J. Virol. 1992, 66(4):1835-1840.
31. McCullough K.C., Parkinson D., Crowther J.R. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 1988, 65(2):187-191.
32. Nishikado H., Mukai K., Kawano Y., Minegishi Y., Karasuyama H. NK cell-depleting anti-asialo gm1 antibody exhibits a lethal off-target effect on basophils in vivo. J. Immunol. 2011, 186(10):5766-5771.
33. Ostrowski M., Vermeulen M., Zabal O., Geffner J.R., Sadir A.M., Lopez O.J. Impairment of thymus-dependent responses by murine dendritic cells infected with foot-and-mouth disease virus. J. Immunol. 2005, 175(6):3971-3979.
34. Ostrowski M., Vermeulen M., Zabal O., Zamorano P.I., Sadir A.M., Geffner J.R., Lopez O.J. The early protective thymus-independent antibody response to foot-and-mouth disease virus is mediated by splenic CD9+ B lymphocytes. J. Virol. 2007, 81(17):9357-9367.
35. Piatti P.G., Berinstein A., Lopez O.J., Borca M.V., Fernandez F., Schudel A.A., Sadir A.M. Comparison of the immune response elicited by infectious and inactivated foot-and-mouth disease virus in mice. J. Gen. Virol. 1991, 72(7):1691-1694.
36. Quattrocchi V., Bianco V., Fondevila N., Pappalardo S., Sadir A., Zamorano P.I. Use of new adjuvants in an emergency vaccine against foot-and-mouth disease virus: evaluation of conferred immunity. Dev. Biol. 2004, 119:481-497.
37. Quattrocchi V., Langellotti C., Pappalardo S., Olivera V., Di Giacomo S., Mongini C., Waldner C., Zamorano P.I. Development of an immuno-modulated vaccine of rapid liberation against foot and mouth disease virus induced immunity. Presented in: The Global Control of FMD Tools, Ideas and Ideals 2008, Erice, Sicily.
38. Rigden R.C., Carrasco C.P., Barnett P.V., Summerfield A., McCullough K.C. Innate immune responses following emergency vaccination against foot-and-mouth disease virus in pigs. Vaccine 2003, 21(13-14):1466-1477.
39. Salguero F.J., Sanchez-Martin M.A., Diaz-San Segundo F., de Avila A., Sevilla N. Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 2005, 332(1):384-396.
40. Salt J.S., Barnett P.V., Dani P., Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 1998, 16(7):746-754.
41. Schijns V., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev. Vaccines 2011, 10(4):539-550.
42. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 2007, 6(5):797-808.
43. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 1994, 174(1-2):83-93.
44. van Rooijen N., Sanders A. Elimination, blocking, and activation of macrophages: three of a kind?. J. Leukoc. Biol. 1997, 62(6):702-709.
45. Vojvodić S., Popović S. Natural killer cells-biology, functions and clinical relevance. Med. Pregl. 2010, 63(1-2):91-97.
46. Yokoyama W.M., Riley J.K. NK cells and their receptors. Reprod. Biomed. 2008, 16(2):173-191.
47. Zandvoort A., Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 2002, 130(1):4-11.